CUAJ, Editor. “Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients With Urological Cancers – Adverse Events (AEs): Management Tool Kit”. Canadian Urological Association Journal 15, no. 1X (May 26, 2026). Accessed May 31, 2026. https://cuaj.ca/index.php/journal/article/view/9883.